草酸艾司西酞普兰治疗卒中后抑郁的疗效及其对患者MMSE评分、ADL评分的影响  

Efficacy of escitalopram oxalate on patients with post stroke depression and its influence on MMSE scores and ADL scores

作　　者：刘伟[1] 赵静雅[1] 尚小龙 吴超 

机构地区：[1]河南大学淮河医院,开封475000

出　　处：《国际精神病学杂志》2018年第1期128-130,共3页Journal Of International Psychiatry

摘　　要：目的探讨草酸艾司西酞普兰治疗卒中后抑郁(PSD)的疗效及其对患者MMSE评分、ADL评分的影响。方法将120例PSD患者随机分为对照组(60例)与观察组(60例),对照组在常规治疗基础上加用疏肝解郁胶囊,观察组在常规治疗基础上加用草酸艾司西酞普兰,采用美国国立卫生研究院卒中量表(NIHSS)、汉密尔顿抑郁量表(HAMD)、经简易智力状态检查量表(MMSE)、日常生活能力量表(ADL)进行疗效评价。结果治疗前,两组患者NIHSS评分、HAMD评分、MMSE评分、ADL评分比较差异无统计学意义(P>0.05);治疗4周后,观察组HAMD评分显著低于对照组(P<0.05),两组患者其余量表评分比较差异无统计学意义(P>0.05);治疗24周后,观察组NIHSS评分、HAMD评分显著低于对照组,MMSE评分、ADL评分显著高于对照组(P<0.05)。结论草酸艾司西酞普兰能够缓解PSD的抑郁症状,改善神经功能和认知功能,提高日常生活能力。Objective To investigate the efficacy of escitalopram oxalate on the patients with post stroke depres- sion （ PSD ） and its influence on MMSE scores and ADL scores. Methods 120 patients with PSD were divided into an control group （ n=60 eases ） and an observation group （ n=60 cases ） randomly, the control group was given Shugan Jieyu capsules baesd on conventional therapy, while the observation group received escitalopram oxalate based on con- ventional therapy, and the efficacy was evaluated by NIHSS, HAMD, MMSE and ADL. Results Before treatment, the scores of NIHSS, HAMD, MMSE and ADL on the patients in the observation group and control group had not obvious differences; After 4 weeks of treatment, the HAMD scores in observation group were obviously lower than those in control group （ P〈0.05 ）, and no obvious differences were found in other scale scores between the 2 groups; After 24 weeks of treatment, the NIHSS and HAMD scores in observation group were obviously lower than those in control group （ P 〈 0.05 ）, while the MMSE and ADL scores in observation group were obviously higher （ P 〈 0.05 ） . Conclusion The escitalopram oxalate can promote neurological function recovery, cognitive dysfunction and activities of daily living, relieve depressive symptoms on PSD patients.

关 键 词：草酸艾司西酞普兰 卒中后抑郁 认知功能障碍 日常生活能力 

分 类 号：R749.05[医药卫生—神经病学与精神病学]